

Jorge R Georgakopoulos

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9584465/jorge-r-georgakopoulos-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

305
citations

12
h-index

16
g-index

38
ext. papers

409
ext. citations

2.5
avg, IF

4.17
L-index

#	Paper	IF	Citations
35	Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 1019-1020	4.5	31
34	Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 155-157	4.5	30
33	Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e32-e34	4.6	23
32	A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 623-626	4.5	21
31	Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 801-803	4.5	21
30	Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1530-1532	4.5	16
29	Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e7-e8	4.6	16
28	Facial and neck erythema associated with dupilumab treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1339-1347	4.5	16
27	Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 290-296	1.6	15
26	Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1212-1214	4.5	14
25	Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series. <i>JAAD Case Reports</i> , 2018 , 4, 310-313	1.4	13
24	Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 174-177	1.6	12
23	Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017 , 21, 452-456	1.6	10
22	Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 953-956	4.5	8
21	Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 391-393	1.6	7
20	Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 422-423	1.6	7
19	Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 591-601	1.6	7

18	Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 424-425	1.6	5
17	A case of rituximab-induced pyoderma gangrenosum. <i>JAAD Case Reports</i> , 2018 , 4, 979-981	1.4	5
16	Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study. <i>JAAD International</i> , 2021 , 4, 67-69	0.9	5
15	Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e416-e418	4.6	4
14	Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1049-1051	4.5	4
13	Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 418-419	1.6	3
12	Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021 , 12034754211049703	1.6	3
11	Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text]. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 468-473	1.6	2
10	Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e485-e487	4.6	2
9	Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series. <i>British Journal of Dermatology</i> , 2019 , 180, 211-212	4	1
8	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020 , 155, 400-410	0.8	1
7	Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 527-528	1.6	1
6	A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy. <i>JAAD International</i> , 2021 , 2, 37-39	0.9	1
5	Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e485-e487	4.6	0
4	A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy.. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022 , 12034754221088556	1.6	0
3	Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 534-535	1.6	0
2	Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 647-649	1.6	0
1	The Utility of IL-17 Inhibitors in Neutrophilic Dermatoses: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021 , 12034754211045389	1.6	0

